|style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers|
|SMILES||Script error: No such module "collapsible list".|
|InChI||Script error: No such module "collapsible list".|
|style="background: #F8EABA; text-align: center;" colspan="2" | Properties|
|Molar mass||637.51 g·mol−1|
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)|
Anacetrapib (USAN, pINN; codenamed MK-0859, Merck) is a CETP inhibitor being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. It is currently in a Phase III trial designed to assess its effects on LDL, HDL, and clinically measurable cardiovascular events, and safety; results are anticipated in 2010.
At the 16th International Symposium on Drugs Affecting Lipid Metabolism (New York, Oct 4-7, 2007), Merck reported on a Phase IIb study. The eight week study reported dosage correlated reduction in LDL-C and increases in HDL-C levels with no corresponding increases in blood pressure in any cohort. The increase in HDL was particularly significant, averaging 44 percent, 86 percent, 139 percent and 133 percent at doses of 10 mg, 40 mg, 150 mg and 300 mg.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|30px||This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it.|
- "Statement on a nonproprietary name adopted by the USAN Council: Anacetrapib" (PDF). American Medical Association. 2007. Retrieved 2008-01-19.
- "Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease". ClinicalTrials.gov. U.S. NIH.
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.